Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | MAOA | P21397 | 6/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21234325 | 0.88 | MAOB (0.67) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL18745392 | 0.86 | MAOB (0.54) | MAOBMAOANR4A2RXRARXRB | |
| SCHEMBL684282 | 0.84 | MAOB (0.62) | MAOBMAOANR4A2 | |
| SCHEMBL18253179 | 0.82 | MAOB (0.66) | MAOBMAOANR4A2MRGPRX4 | |
| SCHEMBL12961031 | 0.81 | MRGPRX4 (0.58) | MAOBMAOAMRGPRX4 | |
| Isopropylamine SCHEMBL9628060 | 0.80 | MAOB (0.65) | MAOBMAOANR4A2PKMRXRA | |
| Formaldehyde SCHEMBL27575662 | 0.80 | KMT2A (0.58) | MAOBMAOANR4A2MRGPRX4 | |
| SCHEMBL9946057 | 0.80 | MAOB (0.60) | MAOBMAOAMRGPRX4 | |
| SCHEMBL791896 | 0.80 | MAOB (0.70) | MAOBMAOANR4A2MRGPRX4 | |
| SCHEMBL10269391 | 0.80 | MAOB (0.64) | MAOBMAOANR4A2PKMRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9464096-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9006229-B2 | Benzothiazole compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | FURIN, NFATC1, NPC1 | MAOB 3570/4885MAOA 3388/4885NR4A2 3905/4885 |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAOB 802/4885MAOA 1118/4885NR4A2 4180/4885 |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FURIN, NFATC1, RUNX1 | MAOB 2806/4885MAOA 3040/4885NR4A2 3615/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | MAOB 1947/4885MAOA 2386/4885NR4A2 2685/4885 |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, NPC1 | MAOB 3593/4885MAOA 3423/4885NR4A2 3878/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAOB 802/4885MAOA 1118/4885NR4A2 4180/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAOB 802/4885MAOA 1118/4885NR4A2 4180/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | MAOB 1947/4885MAOA 2386/4885NR4A2 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.